千金药业(600479) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the period was ¥912,283,647.13, representing a year-on-year growth of 13.61%[5] - Net profit attributable to shareholders was ¥36,939,275.04, an increase of 1.73% compared to the same period last year[5] - Basic earnings per share for the period was ¥0.0906, a slight increase of 0.55% from ¥0.0901 in the previous year[5] - The operating profit for Q1 2021 was CNY 55,455,001.21, slightly higher than CNY 54,460,257.57 in Q1 2020, indicating a growth of 1.8%[24] - The net profit for Q1 2021 was CNY 53,589,994.49, compared to CNY 54,030,492.90 in Q1 2020, showing a decrease of 0.8%[24] - The net profit for Q1 2021 was CNY 24,413,454.39, representing a growth of 1.3% from CNY 24,091,173.56 in Q1 2020[29] - The total comprehensive income for Q1 2021 was CNY 24,413,454.39, compared to CNY 24,091,173.56 in Q1 2020[29] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,270,445,873.64, an increase of 0.99% compared to the end of the previous year[5] - The total liabilities decreased from ¥1,377,761,196.37 to ¥1,328,672,568.77, indicating improved financial stability[17] - Total assets as of March 31, 2021, amounted to ¥4,270,445,873.64, a slight increase from ¥4,228,711,385.05 at the end of 2020[16] - The total liabilities as of March 31, 2021, were CNY 760,223,589.81, down from CNY 764,736,284.97 in the previous year, reflecting a decrease of 0.7%[22] - The total equity as of March 31, 2021, was CNY 1,794,706,675.50, an increase from CNY 1,770,293,221.11 in the previous year, indicating a growth of 1.4%[22] Cash Flow - Net cash flow from operating activities decreased by 44.92% to ¥55,010,376.36 compared to the previous year[5] - Cash inflow from operating activities was CNY 1,035,640,824.10 in Q1 2021, down from CNY 1,181,853,450.14 in Q1 2020[31] - The net cash flow from operating activities for Q1 2021 was -82,729,189.86 RMB, a decrease from 161,973,237.43 RMB in Q1 2020, indicating a significant decline in operational performance[34] - The company reported a net cash flow from investment activities of ¥47,615,570.46, a significant improvement compared to the previous period[14] - The total cash and cash equivalents at the end of Q1 2021 amounted to 591,494,314.46 RMB, compared to 1,322,896,539.54 RMB at the end of Q1 2020, representing a decrease of approximately 55.3%[33] Expenses - Sales expenses increased by 32.03% to ¥281,641,931.18 due to growth in sales scale and significant investment in marketing for new products[13] - R&D expenses rose by 52.43% to ¥26,931,990.75, reflecting increased investment in research and development[13] - The company's sales expenses rose to CNY 105,738,395.68 in Q1 2021, up 62.7% from CNY 64,939,504.68 in Q1 2020[28] - Research and development expenses for Q1 2021 were CNY 26,931,990.75, compared to CNY 17,668,968.25 in Q1 2020, representing a significant increase of 52.4%[24] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,801[10] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., held 28.53% of the shares[10] Other Income - Non-recurring gains and losses for the period totaled ¥978,078.85[9] - The company reported a government subsidy of ¥2,908,936.79 included in non-recurring gains[8] - Other income surged by 231.07% to ¥2,908,936.79, primarily due to increased government subsidies received[13]